Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOFDRA vs COLYTE WITH FLAVOR PACKS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.
Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.
Treatment of cataplexy in patients with narcolepsy,Treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy
Bowel cleansing prior to colonoscopy or barium enema
1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.
Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.
Terminal elimination half-life is 6-9 hours in healthy adults; may be prolonged up to 12-15 hours in patients with hepatic impairment.
Not applicable (non-absorbed; no systemic absorption, thus no elimination half-life in plasma).
Sodium oxybate is primarily metabolized by the enzyme GHB dehydrogenase (a form of aldehyde dehydrogenase) and to a minor extent via CYP450 (not a major pathway). Metabolism is saturable and follows first-order kinetics at therapeutic doses.
Polyethylene glycol 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and metabolized normally.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% excreted unchanged in urine; biliary/fecal elimination accounts for approximately 20% of total clearance.
Primarily fecal (100%) as non-absorbed oral solution; negligible renal or biliary elimination.
Approximately 95% bound to albumin and alpha-1-acid glycoprotein.
Not applicable (non-absorbed; no systemic exposure).
Volume of distribution is 0.8-1.2 L/kg, indicating extensive extravascular distribution.
Not applicable (non-absorbed; no systemic distribution).
Oral bioavailability is approximately 75% due to first-pass metabolism; intravenous bioavailability is 100%.
Oral: negligible systemic bioavailability (<0.1%) due to minimal absorption of polyethylene glycol and electrolytes.
No dosage adjustment required for renal impairment.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment (GFR <30 m L/min) due to risk of fluid and electrolyte abnormalities.
No dosage adjustment required for hepatic impairment.
No specific dose adjustment for hepatic impairment; use standard dosing with caution in severe liver disease due to potential fluid shifts.
Safety and efficacy in pediatric patients have not been established.
Pediatric patients: 25-40 m L/kg/hour until rectal effluent is clear; maximum 4 liters total. Safety and efficacy not established for children under 6 months.
No dosage adjustment required; systemic exposure is similar to that in younger adults.
Elderly: Consider reduced volume (e.g., 2-3 liters) and slower administration rate (e.g., 240 m L every 20 minutes) to mitigate risk of aspiration and electrolyte imbalance.
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and RISK OF ABUSE. SOFDRA is a CNS depressant and can cause respiratory depression, hypotension, profound sedation, coma, and death. Concomitant use of alcohol or other CNS depressants increases these risks. SOFDRA is a Schedule III controlled substance with potential for abuse and dependence.
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES, SEIZURES, AND CARDIAC ARRHYTHMIAS. Use with caution in patients at risk for these conditions. Monitor fluid and electrolyte status.
Central nervous system depression and respiratory depression,Risk of abuse and dependence (Schedule III controlled substance),Sodium content (high sodium intake may be problematic in patients with hypertension, heart failure, or renal impairment),Suicidal ideation and depression (monitor for psychiatric symptoms),Parasomnias (sleepwalking, confusional arousals),Requires strict adherence to dosing schedule (twice nightly, taken at bed and 2.5-4 hours later)
Risk of aspiration, especially in patients with impaired gag reflex or reduced level of consciousness,Fluid and electrolyte disturbances (e.g., hyponatremia, hypokalemia) may occur; monitor in patients with renal or hepatic impairment, heart failure, or those taking diuretics or other drugs affecting electrolytes,Seizures and cardiac arrhythmias have been reported, often in patients with electrolyte imbalances or taking medications that lower seizure threshold,Mucosal ulcerations may occur; avoid use in patients with active inflammatory bowel disease or toxic megacolon,Arrhythmias (e.g., atrial fibrillation, QT prolongation) have been reported,Upper GI bleeding or obstruction; contraindicated in gastric retention or obstruction
Concomitant use of alcohol or other CNS depressants (e.g., benzodiazepines, opioids),Succinic semialdehyde dehydrogenase deficiency,Severe hepatic impairment (Child-Pugh C),History of substance abuse (relative contraindication)
Gastrointestinal obstruction or ileus,Gastric retention or perforation,Bowel perforation,Toxic colitis or toxic megacolon,Hypersensitivity to any component
No significant food interactions; take with or without food. Avoid grapefruit juice? Not clinically significant for SOFDRA.
Avoid all solid foods and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, black coffee, tea without milk, clear fruit juices without pulp, gelatin) are permitted. Do not consume red or purple liquids as they may be mistaken for blood during colonoscopy. Alcohol should be avoided for at least 24 hours prior to the procedure.
Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended human dose; however, anticholinergic drugs may cause fetal tachycardia and reduced fetal heart rate variability. Use in pregnancy should be avoided unless clearly needed. First trimester: limited data; no known major malformations. Second and third trimesters: potential for fetal anticholinergic effects, including decreased fetal movement and heart rate variability.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte shifts could theoretically affect fetal fluid balance, but no known teratogenicity. First trimester: low risk based on lack of systemic absorption. Second/third trimester: theoretical risk of maternal electrolyte imbalance affecting fetal homeostasis, though no specific fetal adverse effects reported.
No data on presence in human milk, effects on breastfed infant, or milk production. Because of the potential for serious adverse reactions (e.g., anticholinergic effects, including constipation and urinary retention) in breastfeeding infants, breastfeeding is not recommended during treatment with sofdr A. M/P ratio unknown.
PEG is not absorbed systemically, thus minimal excretion into breast milk. M/P ratio not applicable/unknown. Considered compatible with breastfeeding as a bowel preparation, but caution with large volumes may alter maternal fluid/electrolyte status, indirectly affecting milk production or composition. Use only if clearly needed.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data in pregnant women. However, consider potential altered absorption and clearance; use lowest effective dose if required. Monitor for increased anticholinergic adverse effects due to possible changes in metabolism.
No specific pharmacokinetic changes in pregnancy requiring dose adjustment due to lack of systemic absorption. However, decreased gastrointestinal motility in pregnancy may prolong colonic transit time; no dose change recommended but monitor for tolerance. Use standard dosing (e.g., 4L in split dose) as in non-pregnant adults, with attention to hydration.
SOFDRA (sofosbuvir 400mg/velpatasvir 100mg) is a pangenotypic NS5B polymerase inhibitor/NS5A inhibitor combination for chronic hepatitis C. Avoid coadministration with strong P-gp inducers (e.g., rifampin, carbamazepine, St. John's wort) which reduce sofosbuvir levels. Monitor for bradycardia when used with amiodarone; consider alternative antiarrhythmic. Dose adjustment not required for mild-moderate renal impairment, but not recommended for severe renal impairment (e GFR <30 m L/min). Test for HBV coinfection prior to initiation; HBV reactivation can occur during and after treatment. Duration: 12 weeks for treatment-naïve or peginterferon/ribavirin-experienced without cirrhosis or with compensated cirrhosis; 24 weeks with ribavirin for decompensated cirrhosis (Child-Pugh B/C). Check sustained virologic response (SVR) at 12 weeks post-treatment.
Colyte with Flavor Packs is a polyethylene glycol 3350-based osmotic laxative used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after administration. Do not use flavor packs containing aspartame in patients with phenylketonuria. Monitor for electrolyte imbalances in patients with renal impairment or those on diuretics. Discontinue if severe bloating, abdominal pain, or vomiting occurs.
Take exactly as prescribed; do not skip doses or stop early without consulting your doctor.,If you have hepatitis B, treatment may reactivate the virus; your doctor will monitor you.,Report any signs of severe bradycardia (fainting, dizziness, chest pain) especially if you take amiodarone.,Avoid St. John's wort, rifampin, and carbamazepine during treatment.,Take with or without food; swallow tablet whole.,Complete full course to achieve cure; missed doses should be taken as soon as remembered unless near next dose.,Use effective contraception during and for 6 months after if partner is of childbearing potential; if used with ribavirin, both partners must use two forms of contraception.
Do not eat any solid food after starting the preparation; only clear liquids are allowed.,Mix the powder with water as directed and refrigerate to improve taste.,Drink the entire solution at the prescribed rate; set a timer if needed.,Expect watery stools; stay near a bathroom during the cleansing process.,Do not add extra flavorings or sweeteners unless provided in the pack.,Contact your doctor if you experience severe nausea, vomiting, or inability to keep the solution down.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOFDRA vs COLYTE WITH FLAVOR PACKS, answered by our medical review team.
SOFDRA is a Stimulant Laxative that works by SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.. COLYTE WITH FLAVOR PACKS is a Osmotic Laxative that works by Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOFDRA and COLYTE WITH FLAVOR PACKS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOFDRA is: 1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.. The standard adult dose of COLYTE WITH FLAVOR PACKS is: Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOFDRA and COLYTE WITH FLAVOR PACKS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOFDRA is classified as Category C. Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended h. COLYTE WITH FLAVOR PACKS is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte sh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.